NASDAQ · Biotechnology

PYPD (PYPD) Stock

$3.80 -4.52% NASDAQ: PYPD Healthcare

Valuation

MetricValue
Price$3.80
Market Cap$38.73M
P/E Ratio-2.32
P/B Ratio4.49
P/S Ratio0.00
EPS (TTM)$-2.09
52-Week High$5.58
52-Week Low$3.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-309.09%
ROA-154.55%
ROCE-300.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.27
Current Ratio1.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-43.0M$-39.0M$-23.0M$-28.0M$-33.0M
Net Profit$-41.0M$-40.0M$-24.0M$-29.0M$-34.0M
EPS$-67.80$-61.20$-16.99$-4.91$-2.09
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$44.0M$26.0M$15.0M$25.0M$22.0M
Total Liabilities$8.0M$20.0M$17.0M$18.0M$11.0M
Cash$10.0M$9.0M$6.0M$16.0M$6.0M
Borrowings$0$14.0M$12.0M$10.0M$3.0M

Latest News

Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid GlobeNewswire · Jul 21, 2026 PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada GlobeNewswire · Jul 21, 2026 PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100 MT Newswires · Jun 1, 2026 PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ GlobeNewswire · Jun 1, 2026 PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference GlobeNewswire · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-34.0M$-17.0M$-22.0M$0
Investing Cash Flow$34.0M$15.0M$4.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$6.0M$-1.0M$-3.0M$10.0M$-9.0M
Free Cash Flow$-35.0M$-36.0M$-17.0M$-22.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield0.00%
Quick Ratio1.63
Interest Coverage-33.00
Return 1Y50.43%
Return 3Y-55.00%
Return 5Y-97.77%

Ownership

Insiders Held21.23%
Institutions Held34.85%
Institutions Float Held44.24%
Institutional HolderSharesReport Date
AIGH Capital Management LLC1,593,5872026-03-31
Rosalind Advisors, Inc.597,9262026-03-31
DAFNA Capital Management, LLC207,9002026-03-31
Morgan Stanley176,8922026-03-31
J. Goldman & Co., L.P.149,4992026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%

About PYPD

PYPD is led by CEO Dikla Czaczkes Akselbrad, employs 57 people, headquartered in IL, publicly traded since 2020.

PYPD stock trades at $3.80 with a market capitalization of $38.73M. The stock is valued at a price-to-earnings (P/E) ratio of -2.32, price-to-book of 4.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.06 and $5.58, and currently trades 31.9% below its 52-week high.

On profitability, PYPD generates a return on equity (ROE) of -309.09%, return on capital employed of -300.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides